Previous Close | 4.400 |
Open | 4.430 |
Bid | 4.360 x N/A |
Ask | 4.430 x N/A |
Day's Range | 4.360 - 4.490 |
52 Week Range | 3.600 - 4.940 |
Volume | |
Avg. Volume | 1,794,244 |
Market Cap | 17.92B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 4.66 |
EPS (TTM) | 0.950 |
Earnings Date | Dec 06, 2021 - Dec 07, 2021 |
Forward Dividend & Yield | 0.16 (3.64%) |
Ex-Dividend Date | May 31, 2022 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for 9993.HK
I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it was ranked among the top companies in five different categories by leading global financial publication Institutional Investor, based on its 2022 All-Asia Executive Team survey. The awards recognize I-Mab's continued strong leadership, corporate governance, ESG strategy, and investor relations capabi